Treatment Response Evaluation of Breast Cancer after Neoadjuvant Chemotherapy and Usefulness of the Imaging Parameters of MRI and PET/CT

다국어 초록 (Multilingual Abstract)

This study was aimed to evaluate the ability of imaging parameters measured on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), diffusion-weighted MRI (DWI) and positron emission tomography/computed tomography (PET/CT) to serve as response markers in breast cancer after neoadjuvant chemotherapy (NAC). In 20 patients with breast cancer, DCE-MRI and DWI using a 3 T scanner and PET/CT were performed before and after NAC. DCE-MRI was analyzed using an automatic computer-aided detection program (MRCAD).
The response imaging parameters were compared with the pathologic response. The areas under the curve (AUCs) for DCE-MRI using MR-CAD analysis, DWI and PET/CT were 0.77, 0.59 and 0.76, respectively. The combination of all parameters measured by MRCAD showed the highest diagnostic performance and accuracy (AUC = 0.77, accuracy = 90%). The combined use of the parameters of PET/CT with DCE-MRI or DWI showed a trend toward improved specificity and negative predictive value (100%, 100%, accuracy = 87.5%). The use of DCE-MRI using MR-CAD parameters indicated better diagnostic performance in predicting the final pathological response compared with DWI and PET/CT, although no statistically significant difference was observed. The combined use of PET/CT with DCE-MRI or DWI may improve the specificity for predicting a pathological response.

참고문헌 (Reference)

1 Lobbes MB, "The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy : a systematic review" 4 : 163-175, 2013

2 Choi JH, "The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer : comparison with ultrasonography and magnetic resonance imaging" 102 : 392-397, 2010

3 Park JS, "The assessment of breast cancer response to neoadjuvant chemotherapy : comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography" 52 : 21-28, 2011

4 Shin HJ, "Prediction of pathologic response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and MRS" 25 : 1349-1359, 2012

5 Gonzalez-Angulo AM, "Overview of resistance to systemic therapy in patients with breast cancer" 608 : 1-22, 2007

6 Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)" 45 : 228-247, 2009

7 Mauri D, "Neoadjuvant versus adjuvant systemic treatment in breast cancer : a meta-analysis" 97 : 188-194, 2005

8 Tateishi U, "Neoadjuvant chemotherapy in breast cancer : prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment" 263 : 53-63, 2012

9 Kong X, "Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients" 47 : 2084-2090, 2011

10 Symmans WF, "Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy" 25 : 4414-4422, 2007

11 Van Goethem M, "MR mammography is useful in the preoperative locoregional staging of breast carcinomas with extensive intraductal component" 62 : 273-282, 2007

12 Hylton NM, "Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL" 263 : 663-672, 2012

13 Wahl RL, "From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors" 50 : 122s-150s, 2009

14 Drew PJ, "Dynamic contrast enhanced magnetic resonance imaging of the breast is superior to triple assessment for the pre-operative detection of multifocal breast cancer" 6 : 599-603, 1999

15 Park SH, "Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer" 22 : 18-25, 2012

16 Wu LM, "Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?" 135 : 17-28, 2012

17 Dose-Schwarz J, "Assessment of residual tumour by FDG-PET : conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer" 102 : 35-41, 2010